Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | BCL9 | O00512 | 1/20 | 0.52 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21097209 | 0.86 | HTR2A (0.53) | HTR2ABCL9CTNNB1GAAMGLL | |
| SCHEMBL21097186 | 0.85 | BCL9 (0.52) | HTR2ABCL9CTNNB1GAAMGLL | |
| SCHEMBL21097090 | 0.82 | BCL9 (0.53) | HTR2ABCL9CTNNB1GAAMGLL | |
| SCHEMBL21057984 | 0.82 | BCL9 (0.50) | HTR2ABCL9CTNNB1GAAMGLL | |
| SCHEMBL18458400 | 0.82 | HTR2A (0.49) | HTR2ABCL9CTNNB1GAAMGLL | |
| SCHEMBL18757959 | 0.82 | HTR2A (0.49) | HTR2ABCL9CTNNB1GAAMGLL | |
| SCHEMBL29716167 | 0.82 | HTR2A (0.52) | HTR2ABCL9CTNNB1GAAMGLL | |
| SCHEMBL278663 | 0.81 | BCL9 (0.62) | HTR2ABCL9CTNNB1GAAMGLL | |
| SCHEMBL409598 | 0.81 | HTR2A (0.59) | HTR2ABCL9CTNNB1GAAMGLL | |
| SCHEMBL29716157 | 0.81 | HTR2A (0.48) | HTR2ABCL9CTNNB1GAAMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441762-B2 | Hepatitis c virus NS3/4A protease inhibitors | UNIVERSITY OF MASSACHUSETTS (US) | 2025-10-14 | — | — | US | disclosed |
| US-12209072-B2 | Cyclopentyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-01-28 | — | — | US | disclosed |
| US-12195444-B2 | Triazole n-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-01-14 | — | — | US | disclosed |
| US-20230339884-A1 | Triazole N-Linked Carbamoyl Cyclohexyl Acids as LPA Antagonists | BRISTOL MYERS SQUIBB CO (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339884-A1 | Triazole N-Linked Carbamoyl Cyclohexyl Acids as LPA Antagonists | BRISTOL MYERS SQUIBB CO (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339884-A1 | Triazole N-Linked Carbamoyl Cyclohexyl Acids as LPA Antagonists | BRISTOL MYERS SQUIBB CO (US) | 2023-10-26 | — | — | US | disclosed |
| US-11697646-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697646-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-07-11 | — | — | US | disclosed |
| EP-3852746-B1 | CYCLOPENTYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-03-29 | — | — | EP | disclosed |
| US-20220324829-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2022-10-13 | — | — | US | disclosed |
| US-20220227806-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | UNIV MASSACHUSETTS (US) | 2022-07-21 | — | — | US | disclosed |
| EP-4011875-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2022-06-15 | — | — | EP | disclosed |
| EP-4011875-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2022-06-15 | — | — | EP | disclosed |
| US-11008300-B2 | Triazole n-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| US-10662172-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-05-26 | — | — | US | disclosed |
| US-20200148665-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-14 | — | — | US | disclosed |
| US-20190185446-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209072-B2 | Cyclopentyl acids as LPA antagonists | LPAR1, LPAR5, LPAR2 | HTR2A 486/4885BCL9 3125/4885CTNNB1 1065/4885 |
| US-20190185446-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | HTR2A 1343/4885BCL9 3739/4885CTNNB1 2136/4885 |
| US-12441762-B2 | Hepatitis c virus NS3/4A protease inhibitors | HAVCR2, CTSC, DPP4 | HTR2A 3305/4885BCL9 807/4885CTNNB1 1528/4885 |
| US-10662172-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | HTR2A 1343/4885BCL9 3739/4885CTNNB1 2136/4885 |
| US-20220227806-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | HAVCR2, CTSC, DPP4 | HTR2A 3305/4885BCL9 807/4885CTNNB1 1528/4885 |
| US-20220324829-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | HTR2A 1343/4885BCL9 3739/4885CTNNB1 2136/4885 |
| US-20200148665-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | HTR2A 1343/4885BCL9 3739/4885CTNNB1 2136/4885 |
| US-11697646-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | HTR2A 1343/4885BCL9 3739/4885CTNNB1 2136/4885 |
| US-20230339884-A1 | Triazole N-Linked Carbamoyl Cyclohexyl Acids as LPA Antagonists | LPAR3, LPAR1, LPAR2 | HTR2A 1343/4885BCL9 3739/4885CTNNB1 2136/4885 |
| US-12195444-B2 | Triazole n-linked carbamoyl cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | HTR2A 1343/4885BCL9 3739/4885CTNNB1 2136/4885 |
| US-11008300-B2 | Triazole n-linked carbamoyl cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | HTR2A 1343/4885BCL9 3739/4885CTNNB1 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.